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CASE REPORT
Somatostatinomas are rare functioning carcinoid tumors that usually arise in the pancreas and duodenum. They
are seldom associated with typical clinical symptoms; their diagnosis is confirmed only by histological and
immunohistochemical studies and the presence of specific hormones. Two distinct clinicopathological forms of
somatostatinoma exist: duodenal and pancreatic somatostatinomas. Clinically, compared to pancreatic somato-
statinomas, duodenal somatostatinomas are more often associated with nonspecific symptoms and neurofibro-
matosis, but less often with somatostatinoma syndrome or metastasis. Histologically, duodenal somatostatinomas
frequently have psammoma bodies in the tumor cells. We report a case of duodenal somatostatinoma in 58-year-
old man with vague epigastric pain and nausea. He did not have diabetes, steatorrhea, or cholelithiasis.
Abdominal computed tomography showed a 25-mm mass in the duodenum and 25-mm nodule in the liver.
Endoscopic retrograde cholangiopancreatography showed a duodenal submucosal tumor. Although the endo-
scopic biopsies were free of malignancy, the patient subsequently underwent Whipple’s operation for the duodenal
mass. Examination revealed as a somatostatinoma using a special stain for somatostatin. (Korean J Intern Med
2011;26:103-107)
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INTRODUCTION
Carcinoid tumors, relatively rare neuroendocrine neo-
plasms arising from enterochromaffin cells, were first
described by Lubarsch in 1888 [1]. Since 1974, functional
neuroendocrine tumors have been classified according to
the major hormones secreted, such as insulinoma, gastri-
noma, VIPoma, glucagonoma, and somatostatinoma.
Since the first two case reports of somatostatin-secreting
tumors in 1977, fewer than 200 cases of somatostatinoma
have been reported [2]. The pancreas is the most common
site of somatostatinoma (68%), followed by the duode-
num (19%), ampulla of Vater (3%), and small intestine
(3%) [3]. Typical somatostatinomas are large, solitary,
malignant tumors that are often discovered with lymph
node or liver metastases at the time of diagnosis [4]. The
clinical presentation includes abdominal pain, nausea,
obstructive jaundice, and endocrinopathy, such as a
somatostatin syndrome. Krejs et al. [5] first reported
somatostatin syndrome in 1979. It is caused by excess
somatostatin released from the somatostatinoma and
consists of the clinical triad of diabetes mellitus, cholelithi-
asis, and steatorrhea [5].
Here, we report a case of a nonfunctional duodenal
somatostatinoma and review gastrointestinal somato-
statinomas.
CASE REPORT
A 58-year-old man was referred to our hospital for eval-
uation of a periampullary mass detected on ultrasonogra-
phy. He had suffered from vague epigastric pain and nau-
sea for about 1 month. Abdominopelvic computed tomog-raphy (CT) revealed a 25-mm mass in the medial side wall
of the second portion of the duodenum at the level of the
ampulla of Vater (Fig. 1A) and a 25-mm ill-defined low-
attenuating nodule in the left medial segment of liver (S4)
(Fig. 1B). The intrahepatic duct, common bile duct (CBD),
and pancreatic duct (PD) were dilated. The total serum
bilirubin was 0.5 mg/dL, and the serum AST/ALT was
38/47 IU/L. Other laboratory findings were normal. The
tumor markers CA19-9, carcinoembryonic antigen, and a-
FP were all in the normal ranges. His fasting blood sugar
was 118 mg/dL, but a glucose tolerance test was normal.
Neither neurofibromatosis nor multiple endocrine neo-
plasms were detected. Endoscopic retrograde cholan-
giopancreatography (ERCP) showed an enlarged ampulla
of Vater covered with a smooth mucosal surface (Fig. 2).
However, the orifice was too narrow to insert the scope for
a cholangiopancreatogram. Endoscopic ultrasonography
revealed a well demarcated mass under the duodenal
mucosa that compressed the distal lumens of the CBD and
PD, and caused dilatation of the proximal CBD and PD
(Fig. 3). Biopsies from ERCP showed only chronic non-
specific duodenitis with lymphocyte infiltration.
Ten days later, the patient underwent Whipple’s opera-
tion (pancreaticoduodenectomy), since the tumor was
highly suspicious for malignancy at endoscopy. At surgery,
a 2.5 × 2.5-cm enlarged ampulla of Vater was found at the
second portion of the duodenum; its surface was smooth
and covered with duodenal mucosa. The regional and
periaortic lymph nodes were enlarged. A hepaticojejunos-
tomy was also performed, and all of the enlarged lymph
nodes were dissected.
The pathological examination showed a 2.3 ×2.3 ×2-cm
mass located mainly in the duodenal submucosa, abutting
the superficial muscle layer of the duodenum (Fig. 4). The
ampulla of Vater was elevated, but free of malignancy. The
tumor was located in the duodenal submucosa and distal
CBD, dilating the CBD. All resected tumor margins and
dissected lymph nodes were free of tumors. A microscopic
examination revealed that the tumor consisted of uniform
cells arranged in solid nests, cords, and glandular patterns
without psammoma bodies (Fig. 5A). The tumor cells
stained for chromogranin A, synaptophysin, and somato-
statin (Fig. 5B). They were argyrophilic on Churukian
Schenk’s staining, but non-argentaffinic on Fontana-
Masson staining. We diagnosed it as a primary duodenal
somatostatinoma.
One month later, he was discharged without complica-
tions. At the 6-month follow-up, abdominopelvic CT
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Figure 1. Abdominal computed tomography shows a well-defined mass at the duodenal second portion (A) and a low-attenuating
nodule in the left medial segment of liver (S4) (B).
A
Figure 2. The endoscopic finding of the duodenal submucosal
tumor and ampulla of Vater (arrow).
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Figure 3. The endoscopic ultrasonography view reveals a 2.6-cm submucosal mass (A), along with common bile duct (arrow) and
pancreatic duct (arrowhead) dilatation (B).
A B
Figure 4. The gross specimen shows an oval mass bulging into the duodenal lumen (2.3 × 2.3 × 2.0 cm, arrow); its surface is covered
with normal duodenal mucosa (A). The cut surface of the tumor is white, granular, and hard. The common bile duct and ampulla of
Vater are free of tumors (B).
Figure 5. A histological section (H&E, × 100) showing tumor cells with a glandular pattern in the duodenal submucosa (A). The
immunohistochemical study was positive for somatostatin (× 200; B).
A B
A Bshowed no recurrent mass and the previous hepatic nod-
ule.
DISCUSSION
A somatostatinoma, a carcinoid tumor arising from
enterochromaffin cells, is a relatively rare neuroendocrine
tumor; the pancreas is the most common site of somato-
statinomas. Somatostatin is a cyclic tetradecapeptide
widely distributed in normal human tissues and secreted
by the hypothalamus, cerebrum, spinal cord, vagus nerve,
and D cells in Langerhans islets of the pancreas, stomach,
duodenum, and small intestine [6]. Somatostatin inhibits
numerous endocrine and exocrine secretory hormones,
including insulin, cholecystokinin, pancreatic enzymes,
and gastrin [4,6]. Nonspecific symptoms such as vague
abdominal pain, nausea, weight loss, and altered bowel
habits are more common than somatostatin syndrome
[4]. Somatostatin syndrome occurs only with pancreatic
somatostatinomas or extrapancreatic tumors larger than
4 cm [4]. Duodenal somatostatinomas are detected rela-
tively earlier and are generally smaller than pancreatic
somatostatinomas. They frequently present with abdomi-
nal pain, obstructive jaundice, cholelithiasis, vomiting,
and abdominal bleeding, rather than typical somatostatin
syndrome [7]. 
In this case, the tumor originated from the duodenum
and was smaller than 4 cm. The patient had only vague
nonspecific symptoms. Unfortunately, the serum insulin,
glucagon, gastrin, somatostatin, and urine 5-hydroxyin-
doleacetic acid (5-HIAA) levels were not checked. Before
the exploratory laparotomy, the tumor was thought to be
an adenocarcinoma of the ampulla of Vater. The serum
somatostatin level is usually elevated in functioning
tumors, although duodenal somatostatinomas are usually
non-secretory. Given the nonspecific symptoms and labo-
ratory findings, microscopic and immunohistochemical
studies typically enable a specific diagnosis. 
The histological features of somatostatinomas are simi-
lar to those of other carcinoid tumors. The tumor cells are
arranged uniformly in trabecular, acinar, ribbon, or cribri-
form structures. They have few mitoses with little necrosis
and are separated by stroma [8]. The most distinct histo-
logical characteristic of somatostatinomas is the psammo-
ma body. These spherical bodies have been reported in
somatostatinomas of the ampulla of Vater, and in pancre-
atic and extrapancreatic somatostatinomas, papillary thy-
roid cancers, serous ovarian tumors, and meningiomas
[9]. Psammoma bodies were reported in 68% of duodenal
somatostatinomas [7].
Most carcinoid tumors stain positively for chromo-
granin A, neuron-specific enolase, Leu-7, and specific
endocrine cell markers. On classical silver staining, 75% to
80% of carcinoid tumors are argyrophilic, while they are
seldom argentaffinic [8]. Since the pathological findings of
our tumor concurred with somatostatinoma, we diag-
nosed it as a duodenal somatostatinoma.
Considering its malignant potential, surgical resection is
the recommended treatment for this tumor. Generally, for
tumors 1 cm or smaller, endoscopic excision is adequate
because of the low incidence of metastasis. For lesions
between 1 and 2 cm, transduodenal excision should be
applied. Larger lesions are more aggressive and invasive.
Tumors larger than 1 cm are likely to invade to deep layer
beyond the submucosa [10] and endoscopic resection can-
not always remove the tumor completely. The malignant
nature of duodenal somatostatinomas and the risk of
metastasis increase significantly in tumors larger than
2 cm. For larger tumors (> 2 cm), Whipple’s operation
with a regional lymphadenectomy should be considered,
even if all of the regional lymph nodes are negative in pre-
operative imaging studies [10]. Regardless of the size of
the primary tumor, if abnormal lymph nodes are detected,
the tumor and all of the regional lymph nodes should be
removed [10]. This recommendation is based on the expe-
rience with duodenal gastrinomas, for which surgical
resection of lymph node appears to improve survival [10].
With liver metastases of neuroendocrine tumors, cytore-
ductive therapy, such as segmentectomy or lobectomy, is
effective. Therefore, somatostatinomas with hepatic
metastases are suitable candidates for hepatic resection.
Since supporting data are lacking, adjuvant chemother-
apy for somatostatinomas is not recommended. Palliative
chemotherapy for unresectable or advanced tumors has
only limited value. Multi-agent regimens, such as combi-
nations of streptozocin, fluorouracil, cyclophosphamide,
or doxorubicin, produce limited responses in patients with
metastatic disease. Octreotide is useful for reducing the
symptoms of somatostatin syndrome in inoperable
patients. The overall 5-year survival for patients with
somatostatinoma is 40% to 60% [4]. The 5-year survival
rate is 40% in somatostatinomas with liver metastasis, but
100% in tumors without liver or lymph node metastases.
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